The virtual BIO CEO & Investor Conference 2021 event, taking place February 16-18, will showcase the Biotechnology Innovation Organization’s (BIO) perspective on the new U.S. Congressional agenda, the record-setting pacing of biotech IPOs and the hottest clinical developments and industry catalysts.
Build on the momentum from JPM Week and experience the best of biotech with three-days of productive BIO One-on-One Partnering meetings with institutional investors, industry analysts, and senior business development executives seeking potential investments and deal partners.
Mogrify’s mission is to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies. Using its proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical.